Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study
PDE5 inhibitor use was consistently associated with improved OS across all male-predominant cancers, including in stage-stratified analyses. These findings support further investigation into the potential role of PDE5 inhibitors in cancer outcomes.
Authors
- Eric V. Mastrolonardo (ORCID: https://orcid.org/0000-0002-2869-8848)
- Adam Luginbuhl (ORCID: https://orcid.org/0000-0001-7682-3108)
- Hani Samarah (ORCID: https://orcid.org/0000-0002-2181-4447)
- A. I. Briskin
- Anika S. Walia
- Julian Jackson (ORCID: https://orcid.org/0000-0002-0182-4904)
- Marina Aweeda (ORCID: https://orcid.org/0000-0001-9360-9592)
- Manal U. Mustafa (ORCID: https://orcid.org/0009-0008-1901-373X)
- Parvesh Kumar
- Sarah R. Harrington (ORCID: https://orcid.org/0009-0002-2940-5418)
- Daniel Uralov
Institutions
- Thomas Jefferson University (US)
- Thomas Jefferson University Hospital (US)
- Sidney Kimmel Cancer Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fonc.2025.1720304
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00